Wet AMD

Ophthalmology·MeSH: Eye Diseases

Prevalence

81.8 / 100K

9 drugs in development·6 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
ABBV-RGX-314	REGENXBIO Inc. (RGNX)
AXPAXLI	OCULAR THERAPEUTIX, INC (OCUL)
Ixo-vec (formerly ADVM-022)	Adverum Biotechnologies, Inc. (ADVM)
surabgene lomparvovec (sura-vec	REGENXBIO Inc. (RGNX)

Phase 2(1)

Drug	Company
ixo-vec	Adverum Biotechnologies, Inc. (ADVM)

Preclinical(3)

Drug	Company
ar-14034 sr	AERIE PHARMACEUTICALS INC (AERI)
szn-8141	Surrozen Inc. (SRZN)
szn-8143	Surrozen Inc. (SRZN)

BLA Filed(1)

Drug	Company
ons-5010/lytenava	Outlook Therapeutics, Inc. (OTLK)

BioSniper tracks 9 drugs in development for Wet AMD across 6 companies.

There are 4 clinical trials targeting Wet AMD tracked by BioSniper.

The estimated prevalence of Wet AMD is approximately 81.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.